Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Renalytix Plc (RNLX)

2.9627   0.003 (0.09%) 02-03 14:27
Open: 2.9 Pre. Close: 2.96
High: 3.1 Low: 2.85
Volume: 54,685 Market Cap: 111(M)

Technical analysis

as of: 2023-02-03 2:50:00 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.08     One year: 4.77
Support: Support1: 2.35    Support2: 1.63
Resistance: Resistance1: 3.5    Resistance2: 4.08
Pivot: 2.9
Moving Average: MA(5): 2.99     MA(20): 2.78
MA(100): 1.8     MA(250): 3.56
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 44.3     %D(3): 49.2
RSI: RSI(14): 60.1
52-week: High: 11.6  Low: 1.04
Average Vol(K): 3-Month: 61 (K)  10-Days: 69 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RNLX ] has closed below upper band by 43.1%. Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.06 - 3.08 3.08 - 3.09
Low: 2.7 - 2.71 2.71 - 2.73
Close: 2.88 - 2.9 2.9 - 2.92

Company Description

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Headline News

Tue, 31 Jan 2023
Is Renalytix PLC (RNLX) a Good Buy in the Health Information Services Industry? - InvestorsObserver

Fri, 20 Jan 2023
Pinnacle Associates Ltd. owns $580,000 of Renalytix Plc (NASDAQ ... - Best Stocks

Tue, 10 Jan 2023
Argo Blockchain: Down But Not Out (Except From My Portfolio ... - Seeking Alpha

Mon, 09 Jan 2023
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems - Yahoo Finance

Wed, 30 Nov 2022
Renalytix Reports Financial Results for First Quarter of Fiscal Year ... - GlobeNewswire

Mon, 31 Oct 2022
Renalytix Reports Full Year Fiscal 2022 Results - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Health Information Services
Shares Out. 0 (M)
Shares Float 36 (M)
% Held by Insiders 3.277e+007 (%)
% Held by Institutions 0 (%)
Shares Short 837 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.989e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 922.8
Return on Equity (ttm) -48.4
Qtrly Rev. Growth 2.61e+006
Gross Profit (p.s.) 16.59
Sales Per Share -48.55
EBITDA (p.s.) 336702
Qtrly Earnings Growth -1.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -37 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.07
Price to Cash Flow 3.35

Stock Dividends

Dividend 0
Forward Dividend 708780
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.